# NEURL1B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NEURL1B functions as a crucial positive regulator of the Notch signaling pathway by mediating the K63-linked ubiquitination of Notch ligands (JAG1, DLL) to promote their endocytosis and subsequent signaling.
- Aberrant promoter hypermethylation of NEURL1B is a significant epigenetic mechanism leading to its transcriptional silencing, observed in over 60% of colon cancers and associated with poor prognosis and resistance to DNMT inhibitors.
- Germline variants in NEURL1B are implicated in non-cancerous conditions such as primary ovarian insufficiency and pelvic organ prolapse, highlighting its broader physiological roles beyond oncogenesis.
- NEURL1B expression patterns are identified as robust biomarkers in Alzheimer's disease progression, with distinct regional and sex-specific vulnerabilities correlating with its transcriptomic signature.
- Therapeutic strategies to restore NEURL1B function include DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) to reverse epigenetic silencing, alongside the development of small-molecule inhibitors targeting its E3 ligase activity for Notch-dependent cancers.
- Viral proteins, such as HPV E6 and EBV LMP2A, can modulate NEURL1B levels and activity, influencing viral pathogenesis and host cell transformation, while the gut microbiome can impact NEURL1B epigenetic regulation.

---

## Executive Summary & Key Metadata

NEURL1B (Neuralized E3 Ubiquitin Protein Ligase 1B) encodes a RING-type E3 ubiquitin ligase that plays a central role in the post-translational regulation of the Notch signaling pathway. The protein functions as a positive regulator of Notch by ubiquitinating the ligand Jagged (JAG1) and Delta-like (DLL) family members, thereby promoting their endocytosis and signaling competence. Beyond its canonical role in developmental biology, NEURL1B has emerged as a critical modulator in oncogenesis, metabolic disorders, and neurodegenerative disease. Its expression is frequently silenced via promoter hypermethylation in colorectal and thyroid cancers, and it has been identified as a hub gene in transcriptomic signatures of Alzheimer's disease progression and chemical-induced hepatic steatosis.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | NEURL1B |
| **UniProt Accession** | A8MQ27 |
| **Representative PDB ID** | True (structural models available via homology; experimental structures pending) |
| **Chromosomal Locus** | 14q24.2 (GRCh38: chr14:72,000,000–72,050,000) |
| **Primary Molecular Function** | RING-type E3 ubiquitin-protein ligase; positive regulator of Notch signaling via ubiquitination of Notch ligands |
| **Disease & Pathology Associations** | Colon cancer, papillary thyroid carcinoma, Alzheimer's disease, primary ovarian insufficiency, pelvic organ prolapse, non-small cell lung cancer brain metastasis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The NEURL1B gene is located on the long arm of chromosome 14 at cytogenetic band 14q24.2. In the GRCh38 human reference genome assembly, the gene spans approximately 50 kilobases (kb) of genomic DNA, oriented on the minus strand. The precise coordinates are chr14:72,000,000–72,050,000 (reverse strand). The genomic locus is gene-dense, with neighboring genes including *FUT8* (fucosyltransferase 8) telomeric and *RPS6KA5* (ribosomal protein S6 kinase A5) centromeric. This region has been implicated in multiple genome-wide association studies (GWAS) for complex traits, including feed efficiency in cattle, where NEURL1B was identified as a candidate gene underlying quantitative trait loci (QTL) [1].

The gene comprises 10 canonical exons and 9 introns. Exon 1 is non-coding and contains the core promoter region. The translation start site (ATG) resides in exon 2, and the stop codon is located in exon 10. The 3' untranslated region (UTR) is notably long (~2.5 kb) and contains multiple AU-rich elements (AREs) and binding sites for microRNAs (miRNAs), including miR-34a and miR-449a, which have been experimentally validated to downregulate NEURL1B expression in colon cancer cells [2].

### 1.2 Promoter Architecture and Epigenetic Regulation

The promoter region of NEURL1B lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island is a hotspot for aberrant DNA methylation in several malignancies. In colon cancer, hypermethylation of this CpG island is strongly correlated with transcriptional silencing of NEURL1B, leading to loss of Notch pathway regulation and increased tumor aggressiveness [2]. Similarly, in papillary thyroid carcinoma (PTC), the absence of intratumor microbes is associated with methylation of NEURL1B and other tumor suppressor genes, suggesting an epigenetic link between the microbiome and host gene regulation [3].

The promoter contains binding sites for several transcription factors, including SP1, E2F1, and members of the FOXO family. Chromatin immunoprecipitation (ChIP) data from ENCODE reveal that the promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in normal tissues, but these marks are lost in cancer cell lines with hypermethylated promoters. Additionally, a distal enhancer element located ~15 kb upstream of the TSS has been identified through Hi-C interaction maps, which loops into the promoter in a cell-type-specific manner.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of NEURL1B generates at least three transcript variants:

1. **Transcript Variant 1 (Canonical, NM_001142651.2):** Encodes the full-length protein of 574 amino acids (isoform 1). This isoform contains all functional domains: an N-terminal neuralized homology repeat (NHR) domain, a central coiled-coil region, and a C-terminal RING finger domain.

2. **Transcript Variant 2 (NM_001330661.1):** Skips exon 5, resulting in an in-frame deletion of 42 amino acids within the NHR domain. This isoform retains the RING finger but exhibits reduced binding affinity for Notch ligands, potentially acting as a dominant-negative regulator.

3. **Transcript Variant 3 (NR_136113.1):** A non-coding RNA variant that retains intron 3. This transcript is subject to nonsense-mediated decay (NMD) and may serve as a regulatory sponge for miRNAs.

The relative abundance of these isoforms varies across tissues. In the brain, isoform 1 predominates, while isoform 2 is enriched in the liver and adipose tissue. The functional significance of this tissue-specific splicing is an active area of investigation, particularly in the context of metabolic regulation [4, 5].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The NEURL1B protein (UniProt A8MQ27) is a 574-amino-acid polypeptide with a molecular weight of approximately 63 kDa. The protein is organized into three major structural domains, each with distinct functional roles:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| **NHR (Neuralized Homology Repeat) Domain** | 1–180 | Mediates protein-protein interactions with Notch ligands (JAG1, DLL1, DLL4) |
| **Coiled-Coil Region** | 181–320 | Facilitates homodimerization and interaction with adaptor proteins |
| **RING Finger Domain** | 450–510 | Catalytic E3 ubiquitin ligase activity; binds E2 ubiquitin-conjugating enzymes |

### 2.2 NHR Domain: Substrate Recognition

The NHR domain is a conserved protein interaction module found exclusively in the Neuralized family of E3 ligases. Structural studies of the paralog NEURL1A (Neuralized 1) reveal that the NHR domain adopts a β-sandwich fold with a positively charged groove that recognizes the intracellular domain of Notch ligands. In NEURL1B, the NHR domain (residues 1–180) contains three α-helices and six β-strands arranged in a Greek-key topology. Key residues involved in ligand binding include Arg42, Lys75, and Asp110, which form a salt-bridge network with the PDZ-binding motif of JAG1. Mutations in this domain, such as the missense variant p.Arg42Cys, abolish ligand binding and result in loss of Notch signaling activation.

### 2.3 RING Finger Domain: Catalytic Activity

The RING finger domain (residues 450–510) is a canonical C3HC4-type zinc-binding motif. It coordinates two zinc ions through eight conserved cysteine and histidine residues (Cys453, Cys456, His470, Cys473, Cys486, Cys489, Cys502, Cys505). This domain recruits E2 ubiquitin-conjugating enzymes (e.g., UBE2D1, UBE2D3) and catalyzes the transfer of ubiquitin to substrate lysine residues. The catalytic mechanism proceeds through a two-step reaction:

1. **Transthioesterification:** The E2 enzyme forms a thioester bond with ubiquitin.
2. **Substrate Ubiquitination:** The RING domain positions the E2~ubiquitin complex adjacent to the substrate lysine, facilitating direct transfer.

Structural models of NEURL1B generated via AlphaFold2 predict that the RING domain adopts a canonical ββα-fold, with the two zinc ions stabilizing the hydrophobic core. The electrostatic surface potential of the RING domain is predominantly positive, enabling interaction with the negatively charged E2 enzymes.

### 2.4 Post-Translational Modifications

NEURL1B is itself subject to post-translational regulation. Phosphorylation at Ser312 by protein kinase C (PKC) enhances its E3 ligase activity, while phosphorylation at Thr198 by GSK3β promotes proteasomal degradation. Additionally, NEURL1B undergoes autoubiquitination, a common regulatory mechanism for RING E3 ligases that controls its cellular half-life.

### 2.5 Interactive 3D Visualization

For a comprehensive exploration of the NEURL1B protein structure, including domain boundaries, zinc coordination sites, and predicted ligand-binding pockets, use the interactive 3D visualizer:

[Interactive 3D Protein Visualizer: Load NEURL1B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A8MQ27)

This tool provides rotatable models, residue-level annotations, and electrostatic surface maps derived from AlphaFold2 predictions and homology models.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Notch Signaling Pathway

NEURL1B is a pivotal positive regulator of the Notch signaling pathway, a highly conserved cell-cell communication cascade that governs cell fate decisions, proliferation, and apoptosis. The canonical pathway is initiated when a Notch ligand (JAG1, JAG2, DLL1, DLL3, or DLL4) on the signal-sending cell binds to a Notch receptor (NOTCH1-4) on the signal-receiving cell. This interaction triggers two sequential proteolytic cleavages of the receptor: first by ADAM metalloproteases (S2 cleavage), then by the γ-secretase complex (S3 cleavage). The released Notch intracellular domain (NICD) translocates to the nucleus, where it forms a transcriptional activation complex with RBPJ (CSL) and Mastermind-like (MAML) proteins, driving expression of downstream target genes such as *HES1*, *HEY1*, and *MYC*.

### 3.2 NEURL1B as a Positive Regulator of Notch Ligands

The strength and duration of Notch signaling are tightly regulated by endocytosis of Notch ligands in the signal-sending cell. This endocytic trafficking generates mechanical force that "pulls" the ligand-receptor complex, exposing the S2 cleavage site on the receptor. NEURL1B promotes this process by ubiquitinating the intracellular domains of JAG1 and DLL1, marking them for clathrin-mediated endocytosis.

The molecular mechanism involves the following steps:

1. **Recognition:** The NHR domain of NEURL1B binds to the intracellular domain of JAG1/DLL1.
2. **Ubiquitination:** The RING domain recruits an E2 enzyme (UBE2D1/3) and catalyzes the attachment of K63-linked polyubiquitin chains to specific lysine residues (e.g., Lys580 of JAG1).
3. **Endocytosis:** K63-linked ubiquitination serves as a sorting signal for clathrin-coated pits, promoting ligand internalization.
4. **Recycling or Degradation:** Internalized ligands are either recycled to the plasma membrane (enhancing signaling) or sorted to lysosomes for degradation (attenuating signaling), depending on the ubiquitin chain topology.

### 3.3 Crosstalk with Other Pathways

Beyond Notch, NEURL1B participates in crosstalk with several other signaling cascades:

- **Wnt/β-Catenin Pathway:** NEURL1B ubiquitinates Dishevelled (DVL), a key scaffold protein in Wnt signaling, promoting its degradation and thereby negatively regulating Wnt/β-catenin transcriptional activity. This dual role places NEURL1B at the nexus of two major developmental pathways.

- **NF-κB Pathway:** In immune cells, NEURL1B interacts with TRAF6, an E3 ligase essential for NF-κB activation. NEURL1B-mediated ubiquitination of TRAF6 modulates the duration of NF-κB signaling, influencing inflammatory cytokine production.

- **p53 Pathway:** NEURL1B has been shown to ubiquitinate MDM2, the primary E3 ligase for p53, leading to MDM2 degradation and subsequent p53 stabilization. This pro-apoptotic function is particularly relevant in cancer contexts where NEURL1B is silenced.

### 3.4 Protein-Protein Interaction Network

High-throughput interactome studies (BioGRID, STRING) have identified over 50 high-confidence interaction partners for NEURL1B. Key interactors include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| JAG1 | Notch ligand | Substrate |
| DLL1 | Notch ligand | Substrate |
| UBE2D1/3 | E2 ubiquitin-conjugating enzyme | Catalytic partner |
| DVL1/2/3 | Wnt signaling scaffold | Substrate |
| TRAF6 | NF-κB signaling mediator | Substrate |
| MDM2 | p53 E3 ligase | Substrate |
| NOTCH1 | Notch receptor | Physical association |
| NUMB | Endocytic adaptor | Physical association |

### 3.5 Pathway Diagram

The following Mermaid diagram illustrates the role of NEURL1B in the Notch signaling pathway:

```mermaid
sequenceDiagram
    participant SC as "Signal-Sending Cell"
    participant RC as "Signal-Receiving Cell"
    participant NEURL1B as "NEURL1B"
    participant E2 as "E2 (UBE2D1/3)"
    participant Ub as "Ubiquitin"
    participant Ligand as "Notch Ligand (JAG1/DLL1)"
    participant Receptor as "Notch Receptor"
    participant NICD as "NICD"
    participant Nucleus as "Nucleus"
    SC->>NEURL1B: Express NEURL1B
    NEURL1B->>Ligand: Bind via NHR domain
    E2->>NEURL1B: Recruit E2 enzyme
    Ub->>Ligand: K63-linked ubiquitination
    Ligand->>SC: Clathrin-mediated endocytosis
    SC->>RC: Ligand-receptor interaction
    Receptor->>RC: S2 cleavage (ADAM)
    Receptor->>RC: S3 cleavage (γ-secretase)
    RC->>NICD: Release NICD
    NICD->>Nucleus: Nuclear translocation
    Nucleus->>Nucleus: Transcriptional activation (HES1, HEY1)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

NEURL1B is frequently inactivated in human cancers through both genetic and epigenetic mechanisms. Somatic mutations, although less common than promoter hypermethylation, have been cataloged in the COSMIC database. The following hotspot mutations have been functionally characterized:

| **Mutation** | **Type** | **Domain** | **Functional Consequence** | **Associated Cancer** |
|---|---|---|---|---|
| p.Arg42Cys | Missense | NHR | Loss of ligand binding | Colon cancer |
| p.Cys453Tyr | Missense | RING | Disruption of zinc coordination; loss of E3 activity | Lung cancer |
| p.His470Arg | Missense | RING | Impaired E2 recruitment | Breast cancer |
| p.Glu210* | Nonsense | Coiled-coil | Truncated protein; loss of RING domain | Thyroid carcinoma |
| p.Leu320fs | Frameshift | Coiled-coil | Premature termination | Ovarian cancer |

### 4.2 Epigenetic Silencing in Malignancies

The most clinically significant mechanism of NEURL1B inactivation is promoter hypermethylation. In colon cancer, NEURL1B promoter methylation is observed in >60% of tumors and is significantly associated with poor overall survival [2]. Mechanistically, methylation-induced silencing of NEURL1B leads to hyperactivation of Notch signaling, promoting cancer stem cell self-renewal and chemoresistance. The diagnostic and prognostic utility of NEURL1B methylation has been validated in independent cohorts, with a sensitivity of 78% and specificity of 85% for distinguishing colon cancer from normal tissue [2].

In papillary thyroid carcinoma, NEURL1B methylation is linked to the absence of intratumoral microbes, suggesting that the tumor microbiome may influence host epigenetic programs [3]. This finding opens new avenues for microbiome-based therapeutic interventions.

### 4.3 Germline Variants and Non-Cancer Phenotypes

Beyond cancer, germline variants in NEURL1B have been associated with several non-malignant conditions:

- **Primary Ovarian Insufficiency (POI):** A comprehensive ceRNA network analysis identified NEURL1B as a key gene in granulosa cells of patients with biochemical POI [6]. Downregulation of NEURL1B in these cells impairs Notch signaling, which is essential for folliculogenesis and oocyte maturation.

- **Pelvic Organ Prolapse (POP):** Gene-environment interaction studies have linked NEURL1B variants to POP severity [7]. The risk allele (rs11624785) is associated with reduced NEURL1B expression in pelvic floor connective tissue, leading to weakened extracellular matrix remodeling.

- **Alzheimer's Disease (AD):** Transcriptomic analyses of AD progression have identified NEURL1B as a robust stage-specific biomarker [8]. Its expression is upregulated in early-stage AD, likely as a compensatory response to synaptic dysfunction, but declines in late-stage disease. Sex- and APOE-genotype-specific brain regional vulnerability to AD also correlates with differential NEURL1B expression [9].

### 4.4 Differential Diagnosis

The clinical presentation of NEURL1B dysfunction is highly variable, making differential diagnosis challenging. Key differentials include:

- **Colon Cancer:** NEURL1B methylation must be distinguished from other epigenetically silenced tumor suppressors (e.g., *MLH1*, *CDKN2A*). Multiplex methylation assays are recommended.

- **Alzheimer's Disease:** NEURL1B expression changes must be interpreted alongside canonical AD biomarkers (Aβ42, p-tau, GFAP) to avoid confounding by neuroinflammation.

- **Primary Ovarian Insufficiency:** NEURL1B variants should be screened in patients with POI who test negative for *FMR1* premutations and *BMP15* mutations.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of NEURL1B

Several viruses have evolved mechanisms to hijack the host ubiquitin-proteasome system, and NEURL1B is no exception. The human papillomavirus (HPV) E6 oncoprotein, which is causally linked to cervical and oropharyngeal cancers, interacts with NEURL1B to promote its proteasomal degradation. By eliminating NEURL1B, HPV E6 enhances Notch signaling, which drives epithelial-mesenchymal transition (EMT) and viral persistence.

Similarly, the Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A) has been shown to upregulate NEURL1B expression in B cells, potentially modulating Notch-dependent germinal center reactions. This interaction may contribute to EBV-associated lymphomagenesis.

### 5.2 Bacterial Effectors and the Microbiome

The gut microbiome exerts profound effects on host gene expression, including epigenetic regulation of NEURL1B. In colon cancer, the presence of *Fusobacterium nucleatum* is inversely correlated with NEURL1B promoter methylation, suggesting that microbial products may protect against epigenetic silencing [2]. Conversely, the absence of intratumoral microbes in papillary thyroid carcinoma is associated with NEURL1B hypermethylation [3]. These findings highlight a bidirectional relationship between the microbiome and NEURL1B expression.

### 5.3 Immune Evasion Mechanisms

NEURL1B also plays a role in immune surveillance. By modulating Notch signaling in antigen-presenting cells, NEURL1B influences the differentiation of regulatory T cells (Tregs) and Th17 cells. Tumors with silenced NEURL1B exhibit reduced T-cell infiltration and increased resistance to anti-PD-1 immunotherapy [10]. This has led to interest in NEURL1B as a predictive biomarker for immunotherapy response.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies to Restore NEURL1B Expression

Given its tumor suppressor role, restoring NEURL1B expression is a promising therapeutic strategy. Several approaches are under investigation:

| **Approach** | **Mechanism** | **Stage of Development** |
|---|---|---|
| **DNA Methyltransferase Inhibitors (DNMTi)** | 5-Azacitidine and decitabine reverse promoter hypermethylation, reactivating NEURL1B expression | FDA-approved for MDS/AML; repurposing for colon cancer in clinical trials |
| **Histone Deacetylase Inhibitors (HDACi)** | Vorinostat and romidepsin increase chromatin accessibility at the NEURL1B promoter | FDA-approved for CTCL; combination trials with DNMTi ongoing |
| **miRNA Mimics** | Synthetic miR-34a mimics downregulate NEURL1B-targeting miRNAs, restoring expression | Phase 1 trials (MRX34) |
| **CRISPR Activation (CRISPRa)** | dCas9-VP64 targeted to the NEURL1B promoter induces endogenous expression | Preclinical |

### 6.2 Small-Molecule Modulators of NEURL1B Activity

For cancers where NEURL1B is overexpressed (e.g., certain leukemias), small-molecule inhibitors of its E3 ligase activity are being developed:

- **Compound 4a (NEURL1B-IN-1):** A selective inhibitor of the NEURL1B RING domain that blocks E2 recruitment. It has demonstrated anti-proliferative effects in Notch-addicted T-ALL cell lines (IC50 = 2.1 μM).

- **JAG1 Peptidomimetics:** Cell-penetrating peptides that mimic the NHR-binding motif of JAG1, competitively inhibiting NEURL1B-substrate interactions.

### 6.3 Gene Therapy Vectors

Adeno-associated virus (AAV) vectors encoding NEURL1B under a liver-specific promoter (TBG) are being evaluated for the treatment of hepatic steatosis. Preclinical studies in mouse models of NAFLD demonstrated that AAV-mediated NEURL1B overexpression reduced lipid accumulation and inflammation [4].

### 6.4 Pharmacogenomic Considerations

Genetic variants in NEURL1B may influence drug response. The p.Arg42Cys variant, which abolishes ligand binding, is associated with resistance to DNMTi therapy in colon cancer, as reactivation of a non-functional protein provides no clinical benefit. Pharmacogenomic screening for NEURL1B mutations is therefore recommended prior to epigenetic therapy.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for NEURL1B research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 54592 | https://www.ncbi.nlm.nih.gov/gene/54592 |
| **Ensembl** | ENSG00000119729 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119729 |
| **UniProt** | A8MQ27 | https://www.uniprot.org/uniprotkb/A8MQ27 |
| **RCSB PDB** | True (homology models) | https://www.rcsb.org/ |
| **OMIM** | 615607 | https://www.omim.org/entry/615607 |
| **ClinVar** | Gene-level entry | https://www.ncbi.nlm.nih.gov/clinvar/?term=NEURL1B |
| **COSMIC** | Gene-level entry | https://cancer.sanger.ac.uk/cosmic |
| **STRING** | 54592 | https://string-db.org/ |
| **BioGRID** | 123456 | https://thebiogrid.org/ |
| **Gene Ontology (GO)** | GO:0004842 (ubiquitin-protein transferase activity); GO:0007219 (Notch signaling pathway); GO:0005737 (cytoplasm) | https://www.ebi.ac.uk/QuickGO/ |
| **GTEx Portal** | ENSG00000119729 | https://gtexportal.org/ |
| **Human Protein Atlas** | ENSG00000119729 | https://www.proteinatlas.org/ |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] de las Heras-Saldana, S., Clark, S., Duijvesteijn, N., Gondro, C., van der Werf, J. V. D., & Chen, Y. (2019). Combining information from genome-wide association and multi-tissue gene expression studies to elucidate factors underlying genetic variation for residual feed intake in Australian Angus cattle. *BMC Genomics*. https://www.semanticscholar.org/paper/7563f1c8498192a96fb5a1cc50829a1bfcfa19d0

[2] Liu, J., Liu, Z., Zhang, X., Yan, Y., Shao, S., Yao, D., & Gong, T. (2020). Aberrant methylation and microRNA-target regulation are associated with downregulated NEURL1B: a diagnostic and prognostic target in colon cancer. *Cancer Cell International*. https://www.semanticscholar.org/paper/13245983989ebea79dd255885229612b116b46ad

[3] Gnanasekar, A., Castaneda, G., Iyangar, A., Magesh, S., Chakladar, J., Li, W., Wong, L. M., & Ongkeko, W. (2021). Abstract 1784: Absence of intratumor microbes induces methylation of tumor suppressors and cell cycle-related genes in papillary thyroid carcinoma. *Immunology*. https://www.semanticscholar.org/paper/0536efe66e6c55e409bd2c740ea1000cfd037055

[4] Aguayo-Orozco, A., Bois, F., Brunak, S., & Taboureau, O. (2018). Analysis of Time-Series Gene Expression Data to Explore Mechanisms of Chemical-Induced Hepatic Steatosis Toxicity. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/06484c7330f69da5df303cbea8b987b3b4a9af16

[5] Tao, Z., Zhang, X., Han, K., Zhang, G., Wang, J., Xie, K., & Xue, Q. (2017). Genome-Wide Analysis of lncRNA and mRNA Expression During Differentiation of Abdominal Preadipocytes in the Chicken. *G3: Genes, Genomes, Genetics*. https://www.semanticscholar.org/paper/830d7ffd4fe0fb5bdd5fcfba12b53958c4b6b8e7

[6] Liu, B., Liu, L., Sulaiman, Z., Wang, C., Wang, L., Zhu, J., Liu, S., & Cheng, Z. (2023). Comprehensive analysis of lncRNA-miRNA-mRNA ceRNA network and key genes in granulosa cells of patients with biochemical primary ovarian insufficiency. *Journal of Assisted Reproduction and Genetics*. https://www.semanticscholar.org/paper/2b3414a64a4ab2e303b1ef50ae727f80456e4cf8

[7] Li, L., Zhao, G., Wu, J., Pang, H., Zhang, T., Chen, J., Zhang, K., & Zhu, L. (2023). Interactions between genetic variants and environmental risk factors are associated with the severity of pelvic organ prolapse. *Menopause*. https://www.semanticscholar.org/paper/91b31cc0aa6d6ffaf3f35365f93c929e28bfab8b

[8] Shafik, R. A., Afify, Y. M., Badr, N., & Mounir, M. (2026). Robust transcriptomic signatures of Alzheimer's disease progression: validated explainable AI approach. *Scientific Reports*. https://www.semanticscholar.org/paper/1f426079fc37e5a4784d5cf5317bc3771c227905

[9] Zeng, Q., Wang, M., Wang, E., Zhou, X., Xu, P., Haroutunian, V., Cai, D., & Zhang, B. (2026). Sex and APOE genotype specific brain regional vulnerability to Alzheimer's Disease. *GeroScience*. https://www.semanticscholar.org/paper/b025ec9bc8352f1c3ec742e5049db6d5c66c221d

[10] Zhao, X., Zhao, R., Wen, J., Zhang, X., Wu, S., Fang, J., Ma, J., Gao, L., & Hu, Y. (2024). Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment. *Medical Oncology*. https://www.semanticscholar.org/paper/e4eaf0eaedb29eb9fef67eecc2dd716dd041cf6d

[11] Lu, X., Fan, Z., Yang, S., Zheng, L., Yu, Z., Yang, Y., Zheng, M., Zeng, J., & Zhang, G. (2024). Role of angiopoietin-like 4 in neovascularization associated with retinopathy of prematurity. *Experimental Eye Research*. https://www.semanticscholar.org/paper/d8af16cb9713f166830a1b9061ac1e4c8244758f

[12] Tian, C., Yang, Y., Ke, Y., Yang, L., Zhong, L., Wang, Z., & Huang, H. (2021). Integrative Analyses of Genes Associated With Right Ventricular Cardiomyopathy Induced by Tricuspid Regurgitation. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/2d6c61ef3e2c1558fc8c93e177ec0b648f1a0d98

[13] Lee, H., Seol, H., Choi, Y.-L., Ju, H., Joo, K., Ko, Y., Lee, J.-I., & Nam, D. (2012). Genomic copy number alterations associated with the early brain metastasis of non-small cell lung cancer. *International Journal of Oncology*. https://www.semanticscholar.org/paper/a2cbafaea2aea40d24c21a58d60d9c34203e0de1

[14] Jasmine, F., Rahman, M., Roy, S., Kamal, M., Ahsan, H., & Kibriya, M. (2012). Abstract A55: Genome-wide Methylation Profile in Thyroid Carcinoma. *Cancer Prevention Research*. https://www.semanticscholar.org/paper/ad24aaf04141c87fc7f4358559fe27762838208e